NCT05892718View on ClinicalTrials.gov

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

May 30, 2027

Study Completion Date

November 15, 2029

Conditions
Advanced Solid TumorRefractory Non-Hodgkin Lymphoma
Interventions
DRUG

HCB101

HCB101 administered via. intravenous (IV) infusion.

Trial Locations (8)

10002

RECRUITING

National Taiwan University Hospital, Taipei

11217

RECRUITING

Taipei Veterans General Hospital, Taipei

23561

RECRUITING

Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City

28078

RECRUITING

Carolina BioOncology, Huntersville

29605

RECRUITING

Greenville Hospital System University Medical Center (ITOR), Greenville

34952

RECRUITING

Hematology-Oncology Associates of the Treasure Coast, Port Saint Lucie

75390

RECRUITING

UT Southwestern Medical Center, Dallas

310000

RECRUITING

Hangzhou First People's Hospital, Hangzhou

Sponsors
All Listed Sponsors
lead

FBD Biologics Limited

INDUSTRY